These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24084658)

  • 1. Perspectives on the PQRI Extractables and Leachables "Safety Thresholds and Best Practices" Recommendations for Inhalation Drug Products.
    Norwood DL; Nagao LM; Stults CL
    PDA J Pharm Sci Technol; 2013; 67(5):413-29. PubMed ID: 24084658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Product Quality Research Institute (PQRI) Leachables and Extractables Working Group Initiatives for Parenteral and Ophthalmic Drug Product (PODP).
    Paskiet D; Jenke D; Ball D; Houston C; Norwood DL; Markovic I
    PDA J Pharm Sci Technol; 2013; 67(5):430-47. PubMed ID: 24084659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Best practices for extractables and leachables in orally inhaled and nasal drug products: an overview of the PQRI recommendations.
    Norwood DL; Paskiet D; Ruberto M; Feinberg T; Schroeder A; Poochikian G; Wang Q; Deng TJ; DeGrazio F; Munos MK; Nagao LM
    Pharm Res; 2008 Apr; 25(4):727-39. PubMed ID: 18183477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of safety qualification thresholds and their use in orally inhaled and nasal drug product evaluation.
    Ball D; Blanchard J; Jacobson-Kram D; McClellan RO; McGovern T; Norwood DL; Vogel W; Wolff R; Nagao L
    Toxicol Sci; 2007 Jun; 97(2):226-36. PubMed ID: 17369604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Principles for Management of Extractables and Leachables in Ophthalmic Drug Products.
    Houston CT; Rodrigues AD; Smith BB; Wang T; Richardson M
    PDA J Pharm Sci Technol; 2022; 76(3):278-294. PubMed ID: 35169039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
    Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I
    PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A compilation of safety impact information for extractables associated with materials used in pharmaceutical packaging, delivery, administration, and manufacturing systems.
    Jenke D; Carlson T
    PDA J Pharm Sci Technol; 2014; 68(5):407-55. PubMed ID: 25336416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simulated Leaching (Migration) Study for a Model Container-Closure System Applicable to Parenteral and Ophthalmic Drug Products.
    Jenke D; Egert T; Hendricker A; Castner J; Feinberg T; Houston C; Hunt DG; Lynch M; Nicholas K; Norwood DL; Paskiet D; Ruberto M; Smith EJ; Holcomb F; Markovic I
    PDA J Pharm Sci Technol; 2017; 71(2):68-87. PubMed ID: 27974627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of mass spectrometry and related techniques in the analysis of extractable and leachable chemicals.
    Sica VP; Krivos KL; Kiehl DE; Pulliam CJ; Henry ID; Baker TR
    Mass Spectrom Rev; 2020 Mar; 39(1-2):212-226. PubMed ID: 30921495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recommendation of Single Time Point Leachables Testing for Lyophilized Biotechnology Products Stored in Rubber Stoppered Glass Vial Systems.
    Gallegos A; Liu J; Ronk M; Qi L; Li K; Semin D; Nashed-Samuel Y
    J Pharm Sci; 2022 Jun; 111(6):1599-1604. PubMed ID: 35257694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing safety of extractables from materials and leachables in pharmaceuticals and biologics - Current challenges and approaches.
    Broschard TH; Glowienke S; Bruen US; Nagao LM; Teasdale A; Stults CL; Li KL; Iciek LA; Erexson G; Martin EA; Ball DJ
    Regul Toxicol Pharmacol; 2016 Nov; 81():201-211. PubMed ID: 27569203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitization Assessment of Extractables and Leachables in Pharmaceuticals: ELSIE Database Analysis.
    Parris P; Whelan G; Burild A; Whritenour J; Bruen U; Bercu J; Callis C; Chilton ML; Graham J; Johann E; Johnson C; Griffin T; Kohan M; Martin EA; Masuda-Herrera M; Stanard B; Cruz MT; Nagao L
    PDA J Pharm Sci Technol; 2024 Aug; 78(4):399-444. PubMed ID: 37714567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standardization of Chromatographic Screening Methods for Organic Extractables and Leachables by Managing Outcomes.
    Jenke D
    PDA J Pharm Sci Technol; 2023; 77(4):329-338. PubMed ID: 37001885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of safety and quality impact of extractable and leachable substances in therapeutic biologic protein products: a risk-based perspective.
    Markovic I
    Expert Opin Drug Saf; 2007 Sep; 6(5):487-91. PubMed ID: 17877437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Safety Risk-Based Extractables and/or Leachables Qualification Strategy for Packaged Drug Products.
    Jenke D
    PDA J Pharm Sci Technol; 2021; 75(6):506-535. PubMed ID: 33990423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and quantification of medical device extractables and leachables via non-target analysis (NTA); Analytical uncertainty.
    Jenke D; Christiaens P; Heise T
    J Pharm Biomed Anal; 2024 Apr; 241():115985. PubMed ID: 38301578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extractables characterization for five materials of construction representative of packaging systems used for parenteral and ophthalmic drug products.
    Jenke D; Castner J; Egert T; Feinberg T; Hendricker A; Houston C; Hunt DG; Lynch M; Shaw A; Nicholas K; Norwood DL; Paskiet D; Ruberto M; Smith EJ; Holcomb F
    PDA J Pharm Sci Technol; 2013; 67(5):448-511. PubMed ID: 24084660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extractables and leachables considerations for prefilled syringes.
    Jenke DR
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1591-600. PubMed ID: 24955780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-nitrosamines as "special case" leachables in a metered dose inhaler drug product.
    Norwood DL; Mullis JO; Feinberg TN; Davis LK
    PDA J Pharm Sci Technol; 2009; 63(4):307-21. PubMed ID: 20088245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing relative response factor variation using a multidetector approach for extractables and leachables (E&L) analysis to mitigate the need for uncertainty factors.
    Jordi MA; Rowland K; Liu W; Cao X; Zong J; Ren Y; Liang Z; Zhou X; Louis M; Lerner K
    J Pharm Biomed Anal; 2020 Jul; 186():113334. PubMed ID: 32387747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.